C
Sanofi
SNY
$50.17
$0.601.21%
C
Hold
5/3/2024Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 5/3/2024 due to a significant increase in the valuation index, growth index and efficiency index.
Sanofi (SNY) was upgraded to C- from D+ on 5/3/2024 due to a significant increase in the valuation index, growth index and efficiency index.
D
Sell
4/12/2024Downgrade
Sanofi (SNY) was downgraded to D+ from C- on 4/12/2024 due to a decline in the total return index.
Sanofi (SNY) was downgraded to D+ from C- on 4/12/2024 due to a decline in the total return index.
C
Hold
3/25/2024Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 3/25/2024 due to an increase in the total return index and volatility index.
Sanofi (SNY) was upgraded to C- from D+ on 3/25/2024 due to an increase in the total return index and volatility index.
D
Sell
2/23/2024Downgrade
Sanofi (SNY) was downgraded to D+ from C- on 2/23/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.2445 to -$0.4766, net income declined 138.25% from $1.56B to -$597.5M, and EBIT declined 47.86% from $1.68B to $877.41M.
Sanofi (SNY) was downgraded to D+ from C- on 2/23/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.2445 to -$0.4766, net income declined 138.25% from $1.56B to -$597.5M, and EBIT declined 47.86% from $1.68B to $877.41M.
C
Hold
2/21/2024Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 2/21/2024 due to an increase in the volatility index and valuation index.
Sanofi (SNY) was upgraded to C- from D+ on 2/21/2024 due to an increase in the volatility index and valuation index.
D
Sell
2/2/2024Downgrade
Sanofi (SNY) was downgraded to D+ from C- on 2/2/2024 due to a decline in the total return index, efficiency index and growth index.
Sanofi (SNY) was downgraded to D+ from C- on 2/2/2024 due to a decline in the total return index, efficiency index and growth index.
C
Hold
1/10/2024Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 1/10/2024 due to a large increase in the valuation index, growth index and efficiency index.
Sanofi (SNY) was upgraded to C- from D+ on 1/10/2024 due to a large increase in the valuation index, growth index and efficiency index.
D
Sell
10/27/2023Downgrade
Sanofi (SNY) was downgraded to D+ from C- on 10/27/2023 due to a noticeable decline in the volatility index and total return index.
Sanofi (SNY) was downgraded to D+ from C- on 10/27/2023 due to a noticeable decline in the volatility index and total return index.
C
Hold
9/26/2023Downgrade
Sanofi (SNY) was downgraded to C- from C on 9/26/2023 due to a decline in the efficiency index, volatility index and total return index.
Sanofi (SNY) was downgraded to C- from C on 9/26/2023 due to a decline in the efficiency index, volatility index and total return index.
C
Hold
7/31/2023Downgrade
Sanofi (SNY) was downgraded to C from B on 7/31/2023 due to a significant decline in the growth index, valuation index and dividend index. Earnings per share declined from $2.5348 to $1.2445, total revenue declined 1.54% from $11.71B to $11.52B, and EBIT declined 0.84% from $1.7B to $1.68B.
Sanofi (SNY) was downgraded to C from B on 7/31/2023 due to a significant decline in the growth index, valuation index and dividend index. Earnings per share declined from $2.5348 to $1.2445, total revenue declined 1.54% from $11.71B to $11.52B, and EBIT declined 0.84% from $1.7B to $1.68B.
B
Buy
7/21/2023Upgraded
Sanofi (SNY) was upgraded to B from B- on 7/21/2023 due to an increase in the total return index, volatility index and valuation index.
Sanofi (SNY) was upgraded to B from B- on 7/21/2023 due to an increase in the total return index, volatility index and valuation index.
B
Buy
4/28/2023Upgraded
Sanofi (SNY) was upgraded to B- from C+ on 4/28/2023 due to a noticeable increase in the growth index, valuation index and total return index.
Sanofi (SNY) was upgraded to B- from C+ on 4/28/2023 due to a noticeable increase in the growth index, valuation index and total return index.
C
Hold
3/16/2023Upgraded
Sanofi (SNY) was upgraded to C+ from C on 3/16/2023 due to an increase in the volatility index, dividend index and solvency index. The quick ratio increased from 0.69 to 0.98, and debt to equity declined from 0.28 to 0.25.
Sanofi (SNY) was upgraded to C+ from C on 3/16/2023 due to an increase in the volatility index, dividend index and solvency index. The quick ratio increased from 0.69 to 0.98, and debt to equity declined from 0.28 to 0.25.
C
Hold
1/17/2023Upgraded
Sanofi (SNY) was upgraded to C from C- on 1/17/2023 due to an increase in the volatility index and total return index.
Sanofi (SNY) was upgraded to C from C- on 1/17/2023 due to an increase in the volatility index and total return index.
C
Hold
10/28/2022Upgraded
Sanofi (SNY) was upgraded to C- from D on 10/28/2022 due to a significant increase in the growth index, valuation index and efficiency index.
Sanofi (SNY) was upgraded to C- from D on 10/28/2022 due to a significant increase in the growth index, valuation index and efficiency index.
D
Sell
10/20/2022Downgrade
Sanofi (SNY) was downgraded to D from D+ on 10/20/2022 due to a decline in the volatility index and total return index.
Sanofi (SNY) was downgraded to D from D+ on 10/20/2022 due to a decline in the volatility index and total return index.
D
Sell
9/8/2022Downgrade
Sanofi (SNY) was downgraded to D+ from C- on 9/8/2022 due to a decline in the volatility index and total return index.
Sanofi (SNY) was downgraded to D+ from C- on 9/8/2022 due to a decline in the volatility index and total return index.
C
Hold
8/17/2022Downgrade
Sanofi (SNY) was downgraded to C- from C on 8/17/2022 due to a large decline in the volatility index and total return index.
Sanofi (SNY) was downgraded to C- from C on 8/17/2022 due to a large decline in the volatility index and total return index.
C
Hold
7/29/2022Downgrade
Sanofi (SNY) was downgraded to C from C+ on 7/29/2022 due to a large decline in the valuation index, growth index and total return index. Total revenue declined 3.96% from $11.91B to $11.44B, and earnings per share declined from $1.0301 to $1.0006.
Sanofi (SNY) was downgraded to C from C+ on 7/29/2022 due to a large decline in the valuation index, growth index and total return index. Total revenue declined 3.96% from $11.91B to $11.44B, and earnings per share declined from $1.0301 to $1.0006.
C
Hold
6/15/2022Downgrade
Sanofi (SNY) was downgraded to C+ from B- on 6/15/2022 due to a decline in the total return index.
Sanofi (SNY) was downgraded to C+ from B- on 6/15/2022 due to a decline in the total return index.
B
Buy
5/4/2022Downgrade
Sanofi (SNY) was downgraded to B- from B on 5/4/2022 due to a large decline in the growth index, valuation index and efficiency index. EBIT declined 29.67% from $2.04B to $1.43B, net income declined 11.36% from $1.46B to $1.29B, and earnings per share declined from $1.1546 to $1.0301.
Sanofi (SNY) was downgraded to B- from B on 5/4/2022 due to a large decline in the growth index, valuation index and efficiency index. EBIT declined 29.67% from $2.04B to $1.43B, net income declined 11.36% from $1.46B to $1.29B, and earnings per share declined from $1.1546 to $1.0301.
B
Buy
4/29/2022Upgraded
Sanofi (SNY) was upgraded to B from C+ on 4/29/2022 due to a substantial increase in the growth index, valuation index and efficiency index. EBIT increased 101.29% from $1.43B to $2.89B, earnings per share increased from $1.0301 to $1.8034, and net income increased 74.27% from $1.29B to $2.25B.
Sanofi (SNY) was upgraded to B from C+ on 4/29/2022 due to a substantial increase in the growth index, valuation index and efficiency index. EBIT increased 101.29% from $1.43B to $2.89B, earnings per share increased from $1.0301 to $1.8034, and net income increased 74.27% from $1.29B to $2.25B.
C
Hold
4/18/2022Upgraded
Sanofi (SNY) was upgraded to C+ from C on 4/18/2022 due to an increase in the volatility index and total return index.
Sanofi (SNY) was upgraded to C+ from C on 4/18/2022 due to an increase in the volatility index and total return index.
C
Hold
3/21/2022Downgrade
Sanofi (SNY) was downgraded to C from C+ on 3/21/2022 due to a decline in the volatility index.
Sanofi (SNY) was downgraded to C from C+ on 3/21/2022 due to a decline in the volatility index.
C
Hold
2/28/2022Downgrade
Sanofi (SNY) was downgraded to C+ from B on 2/28/2022 due to a significant decline in the growth index, valuation index and efficiency index. EBIT declined 29.66% from $2.04B to $1.43B, net income declined 11.35% from $1.46B to $1.29B, and earnings per share declined from $1.1546 to $1.0302.
Sanofi (SNY) was downgraded to C+ from B on 2/28/2022 due to a significant decline in the growth index, valuation index and efficiency index. EBIT declined 29.66% from $2.04B to $1.43B, net income declined 11.35% from $1.46B to $1.29B, and earnings per share declined from $1.1546 to $1.0302.
B
Buy
1/7/2022Upgraded
Sanofi (SNY) was upgraded to B from B- on 1/7/2022 due to an increase in the total return index and volatility index.
Sanofi (SNY) was upgraded to B from B- on 1/7/2022 due to an increase in the total return index and volatility index.
B
Buy
12/3/2021Downgrade
Sanofi (SNY) was downgraded to B- from B on 12/3/2021 due to a decline in the volatility index and total return index.
Sanofi (SNY) was downgraded to B- from B on 12/3/2021 due to a decline in the volatility index and total return index.
B
Buy
11/3/2021Upgraded
Sanofi (SNY) was upgraded to B from C+ on 11/3/2021 due to a major increase in the growth index, valuation index and efficiency index.
Sanofi (SNY) was upgraded to B from C+ on 11/3/2021 due to a major increase in the growth index, valuation index and efficiency index.
C
Hold
7/30/2021Downgrade
Sanofi (SNY) was downgraded to C+ from B on 7/30/2021 due to a major decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.511 to $1.1549, net income declined 22.72% from $1.89B to $1.46B, and EBIT declined 19.31% from $2.53B to $2.04B.
Sanofi (SNY) was downgraded to C+ from B on 7/30/2021 due to a major decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.511 to $1.1549, net income declined 22.72% from $1.89B to $1.46B, and EBIT declined 19.31% from $2.53B to $2.04B.
B
Buy
4/29/2021Upgraded
Sanofi (SNY) was upgraded to B from B- on 4/29/2021 due to a noticeable increase in the growth index, total return index and efficiency index. EBIT increased 53.81% from $1.64B to $2.53B, earnings per share increased from $1.024 to $1.511, and net income increased 46.49% from $1.29B to $1.89B.
Sanofi (SNY) was upgraded to B from B- on 4/29/2021 due to a noticeable increase in the growth index, total return index and efficiency index. EBIT increased 53.81% from $1.64B to $2.53B, earnings per share increased from $1.024 to $1.511, and net income increased 46.49% from $1.29B to $1.89B.
B
Buy
4/19/2021Upgraded
Sanofi (SNY) was upgraded to B- from C+ on 4/19/2021 due to an increase in the volatility index and total return index.
Sanofi (SNY) was upgraded to B- from C+ on 4/19/2021 due to an increase in the volatility index and total return index.
C
Hold
4/7/2021Upgraded
Sanofi (SNY) was upgraded to C+ from C on 4/7/2021 due to an increase in the volatility index and total return index.
Sanofi (SNY) was upgraded to C+ from C on 4/7/2021 due to an increase in the volatility index and total return index.
C
Hold
3/23/2021Downgrade
Sanofi (SNY) was downgraded to C from C+ on 3/23/2021 due to a noticeable decline in the volatility index and valuation index.
Sanofi (SNY) was downgraded to C from C+ on 3/23/2021 due to a noticeable decline in the volatility index and valuation index.
C
Hold
3/5/2021Downgrade
Sanofi (SNY) was downgraded to C+ from B- on 3/5/2021 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 84.6% from $8.37B to $1.29B, and earnings per share declined from $6.6198 to $1.024.
Sanofi (SNY) was downgraded to C+ from B- on 3/5/2021 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 84.6% from $8.37B to $1.29B, and earnings per share declined from $6.6198 to $1.024.
B
Buy
3/1/2021Downgrade
Sanofi (SNY) was downgraded to B- from B on 3/1/2021 due to a decline in the total return index.
Sanofi (SNY) was downgraded to B- from B on 3/1/2021 due to a decline in the total return index.
B
Buy
12/17/2020Upgraded
Sanofi (SNY) was upgraded to B from B- on 12/17/2020 due to an increase in the volatility index and valuation index.
Sanofi (SNY) was upgraded to B from B- on 12/17/2020 due to an increase in the volatility index and valuation index.
B
Buy
12/2/2020Downgrade
Sanofi (SNY) was downgraded to B- from B on 12/2/2020 due to a decline in the total return index.
Sanofi (SNY) was downgraded to B- from B on 12/2/2020 due to a decline in the total return index.
B
Buy
11/17/2020Upgraded
Sanofi (SNY) was upgraded to B from B- on 11/17/2020 due to an increase in the growth index, volatility index and valuation index.
Sanofi (SNY) was upgraded to B from B- on 11/17/2020 due to an increase in the growth index, volatility index and valuation index.
B
Buy
7/31/2020Upgraded
Sanofi (SNY) was upgraded to B- from C on 7/31/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 75,688.66% from -$11.07M to $8.37B, earnings per share increased from -$0.0116 to $6.6198, and EBIT increased 62.99% from $952.26M to $1.55B.
Sanofi (SNY) was upgraded to B- from C on 7/31/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 75,688.66% from -$11.07M to $8.37B, earnings per share increased from -$0.0116 to $6.6198, and EBIT increased 62.99% from $952.26M to $1.55B.
C
Hold
6/30/2020Upgraded
Sanofi (SNY) was upgraded to C from C- on 6/30/2020 due to an increase in the total return index and volatility index.
Sanofi (SNY) was upgraded to C from C- on 6/30/2020 due to an increase in the total return index and volatility index.
C
Hold
6/15/2020Downgrade
Sanofi (SNY) was downgraded to C- from C on 6/15/2020 due to a decline in the volatility index, valuation index and total return index.
Sanofi (SNY) was downgraded to C- from C on 6/15/2020 due to a decline in the volatility index, valuation index and total return index.
C
Hold
4/24/2020Upgraded
Sanofi (SNY) was upgraded to C from C- on 4/24/2020 due to a large increase in the valuation index, growth index and efficiency index.
Sanofi (SNY) was upgraded to C from C- on 4/24/2020 due to a large increase in the valuation index, growth index and efficiency index.
C
Hold
3/11/2020Downgrade
Sanofi (SNY) was downgraded to C- from C on 3/11/2020 due to a decline in the total return index and volatility index.
Sanofi (SNY) was downgraded to C- from C on 3/11/2020 due to a decline in the total return index and volatility index.
C
Hold
3/6/2020Downgrade
Sanofi (SNY) was downgraded to C from C+ on 3/6/2020 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 39.64% from $1.58B to $952.26M.
Sanofi (SNY) was downgraded to C from C+ on 3/6/2020 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 39.64% from $1.58B to $952.26M.
C
Hold
2/28/2020Upgraded
Sanofi (SNY) was upgraded to C+ from C on 2/28/2020 due to an increase in the volatility index, valuation index and total return index.
Sanofi (SNY) was upgraded to C+ from C on 2/28/2020 due to an increase in the volatility index, valuation index and total return index.
C
Hold
2/13/2020Downgrade
Sanofi (SNY) was downgraded to C from C+ on 2/13/2020 due to a decline in the volatility index.
Sanofi (SNY) was downgraded to C from C+ on 2/13/2020 due to a decline in the volatility index.
C
Hold
1/10/2020Upgraded
Sanofi (SNY) was upgraded to C+ from C on 1/10/2020 due to an increase in the total return index and volatility index.
Sanofi (SNY) was upgraded to C+ from C on 1/10/2020 due to an increase in the total return index and volatility index.
C
Hold
11/5/2019Upgraded
Sanofi (SNY) was upgraded to C from C- on 11/5/2019 due to a significant increase in the valuation index, efficiency index and growth index.
Sanofi (SNY) was upgraded to C from C- on 11/5/2019 due to a significant increase in the valuation index, efficiency index and growth index.
C
Hold
10/3/2019Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 10/3/2019 due to a large increase in the volatility index and total return index.
Sanofi (SNY) was upgraded to C- from D+ on 10/3/2019 due to a large increase in the volatility index and total return index.
D
Sell
7/31/2019Downgrade
Sanofi (SNY) was downgraded to D+ from C on 7/31/2019 due to a significant decline in the valuation index, efficiency index and dividend index. Net income declined 133.72% from $289.93M to -$97.76M, and total capital declined 1.16% from $95.8B to $94.69B.
Sanofi (SNY) was downgraded to D+ from C on 7/31/2019 due to a significant decline in the valuation index, efficiency index and dividend index. Net income declined 133.72% from $289.93M to -$97.76M, and total capital declined 1.16% from $95.8B to $94.69B.
C
Hold
5/7/2019Upgraded
Sanofi (SNY) was upgraded to C from C- on 5/7/2019 due to a major increase in the valuation index, efficiency index and growth index.
Sanofi (SNY) was upgraded to C from C- on 5/7/2019 due to a major increase in the valuation index, efficiency index and growth index.
C
Hold
4/18/2019Downgrade
Sanofi (SNY) was downgraded to C- from C on 4/18/2019 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.7285 to $0.2317, net income declined 68.1% from $908.79M to $289.93M, and EBIT declined 34.28% from $1.51B to $990.79M.
Sanofi (SNY) was downgraded to C- from C on 4/18/2019 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.7285 to $0.2317, net income declined 68.1% from $908.79M to $289.93M, and EBIT declined 34.28% from $1.51B to $990.79M.
C
Hold
2/25/2019Upgraded
Sanofi (SNY) was upgraded to C from C- on 2/25/2019 due to an increase in the total return index and valuation index.
Sanofi (SNY) was upgraded to C from C- on 2/25/2019 due to an increase in the total return index and valuation index.
C
Hold
2/7/2019Downgrade
Sanofi (SNY) was downgraded to C- from C on 2/7/2019 due to a decline in the volatility index.
Sanofi (SNY) was downgraded to C- from C on 2/7/2019 due to a decline in the volatility index.
C
Hold
11/1/2018Upgraded
Sanofi (SNY) was upgraded to C from C- on 11/1/2018 due to a substantial increase in the valuation index, growth index and volatility index.
Sanofi (SNY) was upgraded to C from C- on 11/1/2018 due to a substantial increase in the valuation index, growth index and volatility index.
C
Hold
9/10/2018Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 9/10/2018 due to an increase in the total return index, volatility index and valuation index.
Sanofi (SNY) was upgraded to C- from D+ on 9/10/2018 due to an increase in the total return index, volatility index and valuation index.
D
Sell
8/2/2018Downgrade
Sanofi (SNY) was downgraded to D+ from C on 8/2/2018 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 4.67% from $1.58B to $1.51B, and total revenue declined 4.35% from $10.57B to $10.11B.
Sanofi (SNY) was downgraded to D+ from C on 8/2/2018 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 4.67% from $1.58B to $1.51B, and total revenue declined 4.35% from $10.57B to $10.11B.
C
Hold
5/1/2018Upgraded
Sanofi (SNY) was upgraded to C from D+ on 5/1/2018 due to a significant increase in the valuation index, growth index and efficiency index.
Sanofi (SNY) was upgraded to C from D+ on 5/1/2018 due to a significant increase in the valuation index, growth index and efficiency index.
D
Sell
3/13/2018Downgrade
Sanofi (SNY) was downgraded to D+ from C on 3/13/2018 due to a substantial decline in the valuation index, growth index and volatility index. Earnings per share declined from $0.9037 to $0.1182, and EBIT declined 19.82% from $1.97B to $1.58B.
Sanofi (SNY) was downgraded to D+ from C on 3/13/2018 due to a substantial decline in the valuation index, growth index and volatility index. Earnings per share declined from $0.9037 to $0.1182, and EBIT declined 19.82% from $1.97B to $1.58B.
C
Hold
12/1/2017Downgrade
Sanofi (SNY) was downgraded to C from C+ on 12/1/2017 due to a decline in the volatility index.
Sanofi (SNY) was downgraded to C from C+ on 12/1/2017 due to a decline in the volatility index.
C
Hold
11/3/2017Upgraded
Sanofi (SNY) was upgraded to C+ from C on 11/3/2017 due to a substantial increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.6634 to $0.9037, and EBIT increased 8.38% from $1.82B to $1.97B.
Sanofi (SNY) was upgraded to C+ from C on 11/3/2017 due to a substantial increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.6634 to $0.9037, and EBIT increased 8.38% from $1.82B to $1.97B.
C
Hold
4/27/2017Upgraded
Sanofi (SNY) was upgraded to C from C- on 4/27/2017 due to an increase in the volatility index, total return index and solvency index.
Sanofi (SNY) was upgraded to C from C- on 4/27/2017 due to an increase in the volatility index, total return index and solvency index.
C
Hold
3/16/2017Upgraded
Sanofi (SNY) was upgraded to C- from D+ on 3/16/2017 due to a major increase in the valuation index, total return index and growth index. EBIT increased 6.97% from $1.7B to $1.82B, and total revenue increased 5.48% from $9.38B to $9.9B.
Sanofi (SNY) was upgraded to C- from D+ on 3/16/2017 due to a major increase in the valuation index, total return index and growth index. EBIT increased 6.97% from $1.7B to $1.82B, and total revenue increased 5.48% from $9.38B to $9.9B.
D
Sell
3/11/2016Downgrade
Sanofi (SNY) was downgraded to D+ from C- on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
Sanofi (SNY) was downgraded to D+ from C- on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
C
Hold
3/8/2016Downgrade
Sanofi (SNY) was downgraded to C- from C on 3/8/2016 due to a major decline in the volatility index, total return index and valuation index.
Sanofi (SNY) was downgraded to C- from C on 3/8/2016 due to a major decline in the volatility index, total return index and valuation index.
C
Hold
7/31/2015Downgrade
Sanofi (SNY) was downgraded to C from C+ on 7/31/2015 due to a large decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.6357 to $0.5518, total revenue declined 8.59% from $11.46B to $10.47B, and EBIT declined 2.23% from $2.19B to $2.14B.
Sanofi (SNY) was downgraded to C from C+ on 7/31/2015 due to a large decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.6357 to $0.5518, total revenue declined 8.59% from $11.46B to $10.47B, and EBIT declined 2.23% from $2.19B to $2.14B.
C
Hold
7/27/2015Downgrade
Sanofi (SNY) was downgraded to C+ from B- on 7/27/2015 due to a decline in the valuation index.
Sanofi (SNY) was downgraded to C+ from B- on 7/27/2015 due to a decline in the valuation index.
B
Buy
7/10/2015Upgraded
Sanofi (SNY) was upgraded to B- from C+ on 7/10/2015 due to an increase in the valuation index, volatility index and total return index.
Sanofi (SNY) was upgraded to B- from C+ on 7/10/2015 due to an increase in the valuation index, volatility index and total return index.
C
Hold
6/12/2015Downgrade
Sanofi (SNY) was downgraded to C+ from B- on 6/12/2015 due to a major decline in the valuation index and total return index.
Sanofi (SNY) was downgraded to C+ from B- on 6/12/2015 due to a major decline in the valuation index and total return index.
B
Buy
5/4/2015Upgraded
Sanofi (SNY) was upgraded to B- from C+ on 5/4/2015 due to a noticeable increase in the valuation index, growth index and volatility index.
Sanofi (SNY) was upgraded to B- from C+ on 5/4/2015 due to a noticeable increase in the valuation index, growth index and volatility index.
C
Hold
4/15/2015Upgraded
Sanofi (SNY) was upgraded to C+ from C on 4/15/2015 due to an increase in the dividend index and growth index. Earnings per share increased from $0.8107 to $1.2713, EBIT increased 11.34% from $1.96B to $2.19B, and total revenue increased 2.55% from $11.17B to $11.46B.
Sanofi (SNY) was upgraded to C+ from C on 4/15/2015 due to an increase in the dividend index and growth index. Earnings per share increased from $0.8107 to $1.2713, EBIT increased 11.34% from $1.96B to $2.19B, and total revenue increased 2.55% from $11.17B to $11.46B.
C
Hold
11/20/2014Downgrade
Sanofi (SNY) was downgraded to C from C+ on 11/20/2014 due to a noticeable decline in the volatility index, total return index and solvency index.
Sanofi (SNY) was downgraded to C from C+ on 11/20/2014 due to a noticeable decline in the volatility index, total return index and solvency index.
C
Hold
10/22/2014Upgraded
Sanofi (SNY) was upgraded to C+ from C on 10/22/2014 due to an increase in the valuation index.
Sanofi (SNY) was upgraded to C+ from C on 10/22/2014 due to an increase in the valuation index.
C
Hold
10/3/2014Downgrade
Sanofi (SNY) was downgraded to C from C+ on 10/3/2014 due to a decline in the volatility index.
Sanofi (SNY) was downgraded to C from C+ on 10/3/2014 due to a decline in the volatility index.
C
Hold
9/18/2014Upgraded
Sanofi (SNY) was upgraded to C+ from C on 9/18/2014 due to an increase in the volatility index, total return index and solvency index.
Sanofi (SNY) was upgraded to C+ from C on 9/18/2014 due to an increase in the volatility index, total return index and solvency index.
C
Hold
8/22/2014Downgrade
Sanofi (SNY) was downgraded to C from C+ on 8/22/2014 due to a decline in the volatility index and valuation index.
Sanofi (SNY) was downgraded to C from C+ on 8/22/2014 due to a decline in the volatility index and valuation index.
C
Hold
8/12/2014Downgrade
Sanofi (SNY) was downgraded to C+ from B on 8/12/2014 due to a significant decline in the growth index, total return index and dividend index. Earnings per share declined from $1.0883 to $0.8107, EBIT declined 5.91% from $2.09B to $1.96B, and total revenue declined 3.97% from $11.63B to $11.17B.
Sanofi (SNY) was downgraded to C+ from B on 8/12/2014 due to a significant decline in the growth index, total return index and dividend index. Earnings per share declined from $1.0883 to $0.8107, EBIT declined 5.91% from $2.09B to $1.96B, and total revenue declined 3.97% from $11.63B to $11.17B.
B
Buy
4/22/2014Upgraded
Sanofi (SNY) was upgraded to B from C+ on 4/22/2014 due to a major increase in the valuation index.
Sanofi (SNY) was upgraded to B from C+ on 4/22/2014 due to a major increase in the valuation index.
C
Hold
3/10/2014Upgraded
Sanofi (SNY) was upgraded to C+ from C on 3/10/2014 due to a significant increase in the growth index, dividend index and solvency index. Earnings per share increased from $0.2186 to $0.5441, the quick ratio increased from 0.87 to 1.23, and EBIT increased 26.24% from $1.65B to $2.09B.
Sanofi (SNY) was upgraded to C+ from C on 3/10/2014 due to a significant increase in the growth index, dividend index and solvency index. Earnings per share increased from $0.2186 to $0.5441, the quick ratio increased from 0.87 to 1.23, and EBIT increased 26.24% from $1.65B to $2.09B.
NASDAQ
05/08/2024 1:34PM Eastern
Quotes delayed
